JP2022553379A - 操作された制御性ｔ細胞 - Google Patents

操作された制御性ｔ細胞 Download PDF

Info

Publication number
JP2022553379A
JP2022553379A JP2022523914A JP2022523914A JP2022553379A JP 2022553379 A JP2022553379 A JP 2022553379A JP 2022523914 A JP2022523914 A JP 2022523914A JP 2022523914 A JP2022523914 A JP 2022523914A JP 2022553379 A JP2022553379 A JP 2022553379A
Authority
JP
Japan
Prior art keywords
tcr
cells
seq
chain
foxp3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553379A5 (enExample
Inventor
ハンス シュタウス，
シャリン トーマス，
オリビエ プレハム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of JP2022553379A publication Critical patent/JP2022553379A/ja
Publication of JP2022553379A5 publication Critical patent/JP2022553379A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022523914A 2019-10-23 2020-10-22 操作された制御性ｔ細胞 Pending JP2022553379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1915359.2 2019-10-23
GB201915359A GB201915359D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
PCT/GB2020/052657 WO2021079120A1 (en) 2019-10-23 2020-10-22 Engineered regulatory t cell

Publications (2)

Publication Number Publication Date
JP2022553379A true JP2022553379A (ja) 2022-12-22
JP2022553379A5 JP2022553379A5 (enExample) 2023-10-19

Family

ID=68728329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523914A Pending JP2022553379A (ja) 2019-10-23 2020-10-22 操作された制御性ｔ細胞

Country Status (8)

Country Link
US (1) US12692297B2 (enExample)
EP (1) EP4048687A1 (enExample)
JP (1) JP2022553379A (enExample)
CN (1) CN114641487A (enExample)
AU (1) AU2020371991A1 (enExample)
CA (1) CA3154615A1 (enExample)
GB (1) GB201915359D0 (enExample)
WO (1) WO2021079120A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227756B2 (en) * 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
AU2020370033A1 (en) 2019-10-23 2022-06-02 Ucl Business Ltd Engineered regulatory T cell
JP2025515116A (ja) * 2022-05-05 2025-05-13 クウェル セラピューティックス リミテッド 制御性ｔ細胞の抑制活性を維持するための方法
KR20250051662A (ko) * 2022-08-12 2025-04-17 아바타 테라퓨틱스 인코포레이티드 안정한 조절 t 세포 및 생산 방법
CN120091826A (zh) * 2022-08-12 2025-06-03 阿巴塔治疗股份有限公司 多发性硬化症的细胞疗法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436383B2 (ja) * 2018-04-18 2024-02-21 ユーシーエル ビジネス リミテッド 操作された調節性ｔ細胞

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
RU2523058C2 (ru) 2012-06-29 2014-07-20 Общество с ограниченной ответственностью "Регенекс" Способ терапии ремиттирующего рассеянного склероза
US9693977B2 (en) 2013-03-15 2017-07-04 President And Fellows Of Harvard College Method of increasing the quantity of colonic T regulatory cells via G-coupled protein receptor 43
WO2014183056A1 (en) 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
JP7013240B2 (ja) 2015-02-16 2022-01-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９～３７７位エピトープに特異的な完全ヒトＴ細胞受容体
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
US20190358258A1 (en) 2015-10-09 2019-11-28 Robert J. Deans Methods for enhancing proliferation of t regulatory cells
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
AU2020370033A1 (en) 2019-10-23 2022-06-02 Ucl Business Ltd Engineered regulatory T cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436383B2 (ja) * 2018-04-18 2024-02-21 ユーシーエル ビジネス リミテッド 操作された調節性ｔ細胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RIDDELL, V.: "Generating Ag-specific Human Regulatory T-cell by TCR Gene Transfer for the Treatment of Rheumatoid", EDINBURGH NAPIER UNIVERSITY, JPN6024040338, 2018, ISSN: 0005579646 *

Also Published As

Publication number Publication date
US12692297B2 (en) 2026-07-28
AU2020371991A1 (en) 2022-06-02
CN114641487A (zh) 2022-06-17
US20220363733A1 (en) 2022-11-17
GB201915359D0 (en) 2019-12-04
WO2021079120A1 (en) 2021-04-29
EP4048687A1 (en) 2022-08-31
CA3154615A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
US20250154532A1 (en) Engineered regulatory t cell
US20220363733A1 (en) Engineered regulatory t cell
CN114641564B (zh) 工程化的调节性t细胞
JP7789666B2 (ja) Ｈｌａ特異的なキメラ抗原受容体
JP2025515116A (ja) 制御性ｔ細胞の抑制活性を維持するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250423